Acute Kidney InjuryDECONGEST-AKINCT07291778
Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness
A study testing Fluid Management in people with Acute Kidney Injury and VExUS, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury, VExUS
- What is being tested?
- Fluid Management
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2026to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults (≥18 years old)
- Admitted to the MICU, MCCU, or CCU within 24 hours of admission
- Acute kidney injury (AKI) (based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria)
- Adequate acoustic windows for a complete VExUS scan
Who cannot join
- < 18 years old
- pregnant women
- End-stage renal disease (ESRD) or prior renal transplant
- Acute tubular necrosis (ATN) defined by urinalysis (≥2+ protein, ≥2+ blood, ≥1 muddy brown cast, ≥1 RBC cast, or ≥1 dysmorphic RBC)'
- Prior Whipple procedures
- currently incarcerated
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, 35294
Timothy I Kennell, MD, PhD, 2059965864, tkennell@uabmc.edu
Steve Fox, MD
About this study
Official title: The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Read the detailed description
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Informed Arm: The treating team receives the patient's VExUS results and management recommendations.
Not-Informed Arm: The treating team remains blinded to all VExUS findings and receives no feedback or recommendations.
Each enrolled patient will undergo two VExUS ultrasound assessments:
Timepoint 1 (enrollment): Two scans are performed by separate operators to assess waveform reliability and inter-user reproducibility.
Timepoint 2 (48-72 hours after enrollment): A single scan is performed along with concurrent collection of serum creatinine, intake/output (I\&O) balance, and renal replacement therapy (RRT) status.
Each VExUS exam includes Doppler evaluation of the inferior vena cava, hepatic vein, portal vein, renal cortical artery, and renal cortical vein. Scans are saved to secure UAB SharePoint storage labeled with an auto-incrementing study ID.
Blinding Procedures
To maintain study integrity and minimize bias, multiple layers of blinding will be employed:
Scanner Blinding: Sonographers performing the VExUS scans are blinded to the patient's randomization status and to all prior scan results. They collect and upload de-identified images labeled only by study ID.
Interpreter Blinding: The attending physician interpreting the scans (the "overreader") is blinded to randomization status during the image interpretation phase. The overreader reviews both scans for quality and assigns a VExUS score (0-3) before randomization status is revealed.
Recruiter/Coordinator Role: The research coordinator (unblinded) maintains the randomization list and is responsible for communicating the overread results to the treating team only for patients in the informed arm.
Primary Team Blinding: For patients in the not-informed arm, the primary clinical team will not receive any VExUS scores or recommendations, and no study-related documentation will be visible in the electronic health record (EHR).
Statistical Blinding: Data analysts will remain blinded to treatment arm allocation until after all primary outcomes are recorded.
Communication and Clinical Guidance
For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score:
VExUS = 0: Recommend a net positive fluid balance.
VExUS = 1: Recommend a net neutral fluid balance.
VExUS >= 2: Recommend a net negative fluid balance.
These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
Data Management and Analysis
Two linked data lists will be maintained:
Master List (PHI-protected): Contains patient identifiers and MRNs, stored on a secure UAB server.
Patient Data List (de-identified): Contains study ID, randomization arm, scan quality, interpreter scores, creatinine values, I\&O data, RRT status, ICU-free days, hospital-free days, and mortality.
All ultrasound procedures are noninvasive and adhere to ACEP emergency ultrasound standards. Protected health information will remain secured on institutional servers, and only de-identified data will be used for analysis.
- Conditions
- Acute Kidney Injury, VExUS
- Being tested
- Fluid Management, No intervention
- Keywords
- VExUS, Fluid Management, Acute Kidney Injury, ICU
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fluid ManagementOther
For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score:
VExUS = 0: Recommend a net positive fluid balance.
VExUS = 1: Recommend a net neutral fluid balance.
VExUS >= 2: Recommend a net negative fluid balance.
These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
No interventionOther
Primary team will not be informed about the patient's VExUS score and will not be given recommendations for fluid management
| Study group | Role | What they receive |
|---|---|---|
| Informed | Experimental | The treating team receives the patient's VExUS results and management recommendations. Receives: Other: Fluid Management |
| Non-informed | Placebo comparator | The treating team remains blinded to all VExUS findings and receives no feedback or recommendations. Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-hospital Mortality
In-hospital mortality: Death from any cause before hospital discharge, within the 30-day window.
Measured: up to 30 days
Renal Replacement Therapy
New receipt of Renal Replacement Therapy (RRT): Receiving dialysis or another form of RRT for the first time.
Measured: up to 30 days
Persistent Renal Dysfunction
Persistent renal dysfunction: The final serum creatinine value before hospital discharge (within 30 days) is 200% (twice) or more of the patient's baseline creatinine value.
Measured: up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start1 Dec 2026 (estimated)
- Primary completion1 Jul 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Steven W Fox, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07291778
- Sponsor's protocol ID
- IRB-300015346
- Other IDs
- UAB
- Acronym
- DECONGEST-AKI
- Status last verified
- Jul 2026
- First submitted
- 5 Dec 2025
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Munoz F, Born P, Bruna M, Ulloa R, Gonzalez C, Philp V, Mondaca R, Blanco JP, Valenzuela ED, Retamal J, Miralles F, Wendel-Garcia PD, Ospina-Tascon GA, Castro R, Rola P, Bakker J, Hernandez G, Kattan E. Coexistence of a fluid responsive state and venous congestion signals in critically ill patients: a multicenter observational proof-of-concept study. Crit Care. 2024 Feb 19;28(1):52. doi: 10.1186/s13054-024-04834-1.
PubMed 38374167Andrei S, Bahr PA, Nguyen M, Bouhemad B, Guinot PG. Prevalence of systemic venous congestion assessed by Venous Excess Ultrasound Grading System (VExUS) and association with acute kidney injury in a general ICU cohort: a prospective multicentric study. Crit Care. 2023 Jun 8;27(1):224. doi: 10.1186/s13054-023-04524-4.
PubMed 37291662Leyba K, Longino A, Ormesher R, Krienke M, Van Ochten N, Zimmerman K, McCormack L, Martin K, Thai T, Furgeson S, Teitelbaum I, Burke J, Douglas I, Gill E. Venous excess ultrasonography (VExUS) captures dynamic changes in volume status surrounding hemodialysis: A multicenter prospective observational study. Res Sq [Preprint]. 2024 Apr 8:rs.3.rs-4185584. doi: 10.21203/rs.3.rs-4185584/v1.
PubMed 38659788Rola P, Miralles-Aguiar F, Argaiz E, Beaubien-Souligny W, Haycock K, Karimov T, Dinh VA, Spiegel R. Clinical applications of the venous excess ultrasound (VExUS) score: conceptual review and case series. Ultrasound J. 2021 Jun 19;13(1):32. doi: 10.1186/s13089-021-00232-8.
PubMed 34146184Melo RH, Gioli-Pereira L, Melo E, Rola P. Venous excess ultrasound score association with acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Ultrasound J. 2025 Mar 3;17(1):16. doi: 10.1186/s13089-025-00413-9.
PubMed 40029471Gomez-Rodriguez C, Tadeo-Espinoza H, Solis-Huerta F, Leal-Villarreal MAJ, Guerrero-Cabrera P, Cruz N, Gaytan-Arocha JE, Soto-Mota A, Vasquez Z, Gamba G, Verbrugge FH, Argaiz ER. Hemodynamic Evaluation of Right-Sided Congestion With Doppler Ultrasonography in Pulmonary Hypertension. Am J Cardiol. 2023 Sep 15;203:459-462. doi: 10.1016/j.amjcard.2023.07.007. Epub 2023 Aug 4. No abstract available.
PubMed 37542955Iida N, Seo Y, Sai S, Machino-Ohtsuka T, Yamamoto M, Ishizu T, Kawakami Y, Aonuma K. Clinical Implications of Intrarenal Hemodynamic Evaluation by Doppler Ultrasonography in Heart Failure. JACC Heart Fail. 2016 Aug;4(8):674-82. doi: 10.1016/j.jchf.2016.03.016. Epub 2016 May 11.
PubMed 27179835Klompmaker P, Mousa A, Allard DJ, Hagen BSH, Banki T, Vermeulen W, de Waal M, van Wolfswinkel S, De Grooth HJS, Veelo DP, Vlaar APJ, Tuinman PR. The association between venous excess ultrasound grading system (VExUS) and major adverse kidney events after 30 days in critically ill patients: A prospective cohort study. J Crit Care. 2025 Aug;88:155097. doi: 10.1016/j.jcrc.2025.155097. Epub 2025 Apr 25.
PubMed 40286489Longino A, Martin K, Leyba K, Siegel G, Thai TN, Riscinti M, Douglas IS, Gill E, Burke J. Prospective Evaluation of Venous Excess Ultrasound for Estimation of Venous Congestion. Chest. 2024 Mar;165(3):590-600. doi: 10.1016/j.chest.2023.09.029. Epub 2023 Oct 7.
PubMed 37813180Trigkidis KK, Siempos II, Kotanidou A, Zakynthinos S, Routsi C, Kokkoris S. EARLY TRAJECTORY OF VENOUS EXCESS ULTRASOUND SCORE IS ASSOCIATED WITH CLINICAL OUTCOMES OF GENERAL ICU PATIENTS. Shock. 2024 Mar 1;61(3):400-405. doi: 10.1097/SHK.0000000000002321. Epub 2024 Feb 27.
PubMed 38517247Prager R, Arntfield R, Wong MYS, Ball I, Lewis K, Rochwerg B, Basmaji J. Venous congestion in septic shock quantified with point-of-care ultrasound: a pilot prospective multicentre cohort study. Can J Anaesth. 2024 May;71(5):640-649. doi: 10.1007/s12630-024-02717-1. Epub 2024 Mar 28.
PubMed 38548949Li ZT, Huang DB, Zhao JF, Li H, Fu SQ, Wang W. Comparison of various surrogate markers for venous congestion in predicting acute kidney injury following cardiac surgery: A cohort study. J Crit Care. 2024 Feb;79:154441. doi: 10.1016/j.jcrc.2023.154441. Epub 2023 Oct 7.
PubMed 37812993Viana-Rojas JA, Argaiz E, Robles-Ledesma M, Arias-Mendoza A, Najera-Rojas NA, Alonso-Bringas AP, De Los Rios-Arce LF, Armenta-Rodriguez J, Gopar-Nieto R, Briseno-De la Cruz JL, Gonzalez-Pacheco H, Sierra-Lara Martinez D, Gonzalez-Salido J, Lopez-Gil S, Araiza-Garaygordobil D. Venous excess ultrasound score and acute kidney injury in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2023 Jul 7;12(7):413-419. doi: 10.1093/ehjacc/zuad048.
PubMed 37154067Utrilla-Alvarez JD, Gopar-Nieto R, Garcia-Cruz E, Lazcano-Diaz E, Jimenez-Rodriguez GM, Rojas-Velasco G, Manzur-Sandoval D. Assessing the venous system: Correlation of mean systemic filling pressure with the venous excess ultrasound grading system in cardiac surgery. Echocardiography. 2023 Nov;40(11):1216-1226. doi: 10.1111/echo.15697. Epub 2023 Sep 23.
PubMed 37742087Longino A, Martin K, Leyba K, Siegel G, Gill E, Douglas IS, Burke J. Correlation between the VExUS score and right atrial pressure: a pilot prospective observational study. Crit Care. 2023 May 26;27(1):205. doi: 10.1186/s13054-023-04471-0.
PubMed 37237315
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function
- ClinicalTrials.gov ID
- NCT07291778
- Acronym / sponsor ID
- DECONGEST-AKI / IRB-300015346
- Conditions
- Acute Kidney Injury, VExUS
- Keywords
- VExUS, Fluid Management, Acute Kidney Injury, ICU
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of Alabama at BirminghamUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 1 Jul 2028 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Detailed description
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Informed Arm: The treating team receives the patient's VExUS results and management recommendations.
Not-Informed Arm: The treating team remains blinded to all VExUS findings and receives no feedback or recommendations.
Each enrolled patient will undergo two VExUS ultrasound assessments:
Timepoint 1 (enrollment): Two scans are performed by separate operators to assess waveform reliability and inter-user reproducibility.
Timepoint 2 (48-72 hours after enrollment): A single scan is performed along with concurrent collection of serum creatinine, intake/output (I\&O) balance, and renal replacement therapy (RRT) status.
Each VExUS exam includes Doppler evaluation of the inferior vena cava, hepatic vein, portal vein, renal cortical artery, and renal cortical vein. Scans are saved to secure UAB SharePoint storage labeled with an auto-incrementing study ID.
Blinding Procedures
To maintain study integrity and minimize bias, multiple layers of blinding will be employed:
Scanner Blinding: Sonographers performing the VExUS scans are blinded to the patient's randomization status and to all prior scan results. They collect and upload de-identified images labeled only by study ID.
Interpreter Blinding: The attending physician interpreting the scans (the "overreader") is blinded to randomization status during the image interpretation phase. The overreader reviews both scans for quality and assigns a VExUS score (0-3) before randomization status is revealed.
Recruiter/Coordinator Role: The research coordinator (unblinded) maintains the randomization list and is responsible for communicating the overread results to the treating team only for patients in the informed arm.
Primary Team Blinding: For patients in the not-informed arm, the primary clinical team will not receive any VExUS scores or recommendations, and no study-related documentation will be visible in the electronic health record (EHR).
Statistical Blinding: Data analysts will remain blinded to treatment arm allocation until after all primary outcomes are recorded.
Communication and Clinical Guidance
For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score:
VExUS = 0: Recommend a net positive fluid balance.
VExUS = 1: Recommend a net neutral fluid balance.
VExUS >= 2: Recommend a net negative fluid balance.
These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
Data Management and Analysis
Two linked data lists will be maintained:
Master List (PHI-protected): Contains patient identifiers and MRNs, stored on a secure UAB server.
Patient Data List (de-identified): Contains study ID, randomization arm, scan quality, interpreter scores, creatinine values, I\&O data, RRT status, ICU-free days, hospital-free days, and mortality.
All ultrasound procedures are noninvasive and adhere to ACEP emergency ultrasound standards. Protected health information will remain secured on institutional servers, and only de-identified data will be used for analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Informed | Experimental | Other: Fluid ManagementThe treating team receives the patient's VExUS results and management recommendations. |
| Non-informed | Placebo comparator | Other: No interventionThe treating team remains blinded to all VExUS findings and receives no feedback or recommendations. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults (≥18 years old)
- Admitted to the MICU, MCCU, or CCU within 24 hours of admission
- Acute kidney injury (AKI) (based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria)
- Adequate acoustic windows for a complete VExUS scan
Key exclusion criteria (6 listed)
- < 18 years old
- pregnant women
- End-stage renal disease (ESRD) or prior renal transplant
- Acute tubular necrosis (ATN) defined by urinalysis (≥2+ protein, ≥2+ blood, ≥1 muddy brown cast, ≥1 RBC cast, or ≥1 dysmorphic RBC)'
- Prior Whipple procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fluid ManagementFor patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score: VExUS = 0: Recommend a net positive fluid balance. VExUS = 1: Recommend a net neutral fluid balance. VExUS >= 2: Recommend a net negative fluid balance. These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team. | Other | Informed |
| No interventionPrimary team will not be informed about the patient's VExUS score and will not be given recommendations for fluid management | Other | Non-informed |
Primary outcome
In-hospital Mortality
Time frame: up to 30 days
In-hospital mortality: Death from any cause before hospital discharge, within the 30-day window.
Renal Replacement Therapy
Time frame: up to 30 days
New receipt of Renal Replacement Therapy (RRT): Receiving dialysis or another form of RRT for the first time.
Persistent Renal Dysfunction
Time frame: up to 30 days
Persistent renal dysfunction: The final serum creatinine value before hospital discharge (within 30 days) is 200% (twice) or more of the patient's baseline creatinine value.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Background: PubMed 38374167Munoz F, Born P, Bruna M, Ulloa R, Gonzalez C, Philp V, Mondaca R, Blanco JP, Valenzuela ED, Retamal J, Miralles F, Wendel-Garcia PD, Ospina-Tascon GA, Castro R, Rola P, Bakker J, Hernandez G, Kattan E. Coexistence of a fluid responsive state and venous congestion signals in critically ill patients: a multicenter observational proof-of-concept study. Crit Care. 2024 Feb 19;28(1):52. doi: 10.1186/s13054-024-04834-1.
- Background: PubMed 37291662Andrei S, Bahr PA, Nguyen M, Bouhemad B, Guinot PG. Prevalence of systemic venous congestion assessed by Venous Excess Ultrasound Grading System (VExUS) and association with acute kidney injury in a general ICU cohort: a prospective multicentric study. Crit Care. 2023 Jun 8;27(1):224. doi: 10.1186/s13054-023-04524-4.
- Background: PubMed 38659788Leyba K, Longino A, Ormesher R, Krienke M, Van Ochten N, Zimmerman K, McCormack L, Martin K, Thai T, Furgeson S, Teitelbaum I, Burke J, Douglas I, Gill E. Venous excess ultrasonography (VExUS) captures dynamic changes in volume status surrounding hemodialysis: A multicenter prospective observational study. Res Sq [Preprint]. 2024 Apr 8:rs.3.rs-4185584. doi: 10.21203/rs.3.rs-4185584/v1.
- Background: PubMed 34146184Rola P, Miralles-Aguiar F, Argaiz E, Beaubien-Souligny W, Haycock K, Karimov T, Dinh VA, Spiegel R. Clinical applications of the venous excess ultrasound (VExUS) score: conceptual review and case series. Ultrasound J. 2021 Jun 19;13(1):32. doi: 10.1186/s13089-021-00232-8.
- Background: PubMed 40029471Melo RH, Gioli-Pereira L, Melo E, Rola P. Venous excess ultrasound score association with acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Ultrasound J. 2025 Mar 3;17(1):16. doi: 10.1186/s13089-025-00413-9.
- Background: PubMed 37542955Gomez-Rodriguez C, Tadeo-Espinoza H, Solis-Huerta F, Leal-Villarreal MAJ, Guerrero-Cabrera P, Cruz N, Gaytan-Arocha JE, Soto-Mota A, Vasquez Z, Gamba G, Verbrugge FH, Argaiz ER. Hemodynamic Evaluation of Right-Sided Congestion With Doppler Ultrasonography in Pulmonary Hypertension. Am J Cardiol. 2023 Sep 15;203:459-462. doi: 10.1016/j.amjcard.2023.07.007. Epub 2023 Aug 4. No abstract available.
- Background: PubMed 27179835Iida N, Seo Y, Sai S, Machino-Ohtsuka T, Yamamoto M, Ishizu T, Kawakami Y, Aonuma K. Clinical Implications of Intrarenal Hemodynamic Evaluation by Doppler Ultrasonography in Heart Failure. JACC Heart Fail. 2016 Aug;4(8):674-82. doi: 10.1016/j.jchf.2016.03.016. Epub 2016 May 11.
- Background: PubMed 40286489Klompmaker P, Mousa A, Allard DJ, Hagen BSH, Banki T, Vermeulen W, de Waal M, van Wolfswinkel S, De Grooth HJS, Veelo DP, Vlaar APJ, Tuinman PR. The association between venous excess ultrasound grading system (VExUS) and major adverse kidney events after 30 days in critically ill patients: A prospective cohort study. J Crit Care. 2025 Aug;88:155097. doi: 10.1016/j.jcrc.2025.155097. Epub 2025 Apr 25.
- Background: PubMed 37813180Longino A, Martin K, Leyba K, Siegel G, Thai TN, Riscinti M, Douglas IS, Gill E, Burke J. Prospective Evaluation of Venous Excess Ultrasound for Estimation of Venous Congestion. Chest. 2024 Mar;165(3):590-600. doi: 10.1016/j.chest.2023.09.029. Epub 2023 Oct 7.
- Background: PubMed 38517247Trigkidis KK, Siempos II, Kotanidou A, Zakynthinos S, Routsi C, Kokkoris S. EARLY TRAJECTORY OF VENOUS EXCESS ULTRASOUND SCORE IS ASSOCIATED WITH CLINICAL OUTCOMES OF GENERAL ICU PATIENTS. Shock. 2024 Mar 1;61(3):400-405. doi: 10.1097/SHK.0000000000002321. Epub 2024 Feb 27.
- Background: PubMed 38548949Prager R, Arntfield R, Wong MYS, Ball I, Lewis K, Rochwerg B, Basmaji J. Venous congestion in septic shock quantified with point-of-care ultrasound: a pilot prospective multicentre cohort study. Can J Anaesth. 2024 May;71(5):640-649. doi: 10.1007/s12630-024-02717-1. Epub 2024 Mar 28.
- Background: PubMed 37812993Li ZT, Huang DB, Zhao JF, Li H, Fu SQ, Wang W. Comparison of various surrogate markers for venous congestion in predicting acute kidney injury following cardiac surgery: A cohort study. J Crit Care. 2024 Feb;79:154441. doi: 10.1016/j.jcrc.2023.154441. Epub 2023 Oct 7.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fluid Management in people with Acute Kidney Injury and VExUS, run by University of Alabama at Birmingham at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Timothy I Kennell, MD, PhD (2059965864, tkennell@uabmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-hospital Mortality (time frame: up to 30 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07291778, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.